Clinical Trial Update: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy and safety of sofosbuvir/velpatasvir fixed-dose combination for 12 weeks in adults with chronic HCV and HIV-1 coinfection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Sofosbuvir/Velpatasvir Fixed Dose Combination (sofosbuvir/velpatasvir)

Snippet

Sponsor: Gilead Sciences | Conditions: Hepatitis C Virus Infection | Phase 3 | Status: COMPLETED | Results posted: 2017-06-01